H. Martin Seidel

Martin was named CEO of IFM Therapeutics in December, 2019 after first joining IFM as Executive Vice President of Research and Development in June, 2017.

Martin joined IFM from Novartis, where he was the Global Head of Strategic Alliances (BD&L) for the Novartis Institutes for Biomedical Research (NIBR) from 2014-17. In that role, he and his team executed more than 70 deals that encompassed in-licenses, out-licenses, collaborations, acquisitions and equity investments with aggregate deal terms of >$1 billion in upfront/committed funds and total deal value >$8 billion. Prior to that, Martin was head of NIBR’s Genomics Institute of the Novartis Research Foundation (GNF), an institute of ~600 associates focused on drug discovery, target discovery and technology development. Over 11 years at GNF, he helped advance more than 40 clinical candidates, including 25 programs that progressed to the clinic, 13 new molecular entities that achieved positive clinical proof of concept and more than nine molecules that are now either FDA-approved drugs (Zykadia™/ceritinib, Odomzo®/sonedegib, Braftovi™/encorafenib, Mayzent® / siponimod) or in late-stage clinical development. He has served as Board Observer with IFM Therapeutics, Luc/Cadent Therapeutics, Surface Oncology, Raze Therapeutics, Arcus Biosciences, Intellia Therapeutics and Caribou Biosciences.

Martin earned his Ph.D. from Harvard University in the laboratory of Jeremy R. Knowles. Prior to his graduate work, he spent a year at the Friedrich-Alexander Universität Erlangen-Nürnberg on a DAAD Fellowship and received his A.B. from Princeton University.